Jeffery W. Kelly, Lita Annenberg Hazen Professor of Chemistry, The Scripps Research Institute
In 2010 there were no regulatory agency approved drugs that slowed neurodegeneration associated with human amyloid diseases. A year later our drug for slowing transthyretin amyloidosis was regulatory agency approved. There are now 10 regulatory agency approved medicines for slowing neurodegeneration, reflecting amazing progress. Kelly will discuss what causes neurodegenerative diseases and how these drugs work to slow the progression of dementia. Elected in 2023, Kelly represents Class I's section on Chemistry.